G Varuni Kondagunta

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Adjuvant chemotherapy for stage II nonseminomatous germ-cell tumors
    G Varuni Kondagunta
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Semin Urol Oncol 20:239-43. 2002
  2. ncbi request reprint Chemotherapy for advanced germ cell tumors
    G Varuni Kondagunta
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:5493-502. 2006
  3. ncbi request reprint Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors
    G Varuni Kondagunta
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:85-90. 2007
  4. ncbi request reprint Adjuvant chemotherapy for stage II nonseminomatous germ cell tumors
    G Varuni Kondagunta
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Urol Clin North Am 34:179-85; abstract ix. 2007
  5. ncbi request reprint Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors
    G Varuni Kondagunta
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 23:9290-4. 2005
  6. ncbi request reprint Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors
    G Varuni Kondagunta
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:6549-55. 2005
  7. ncbi request reprint Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy
    G Varuni Kondagunta
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 22:464-7. 2004
  8. ncbi request reprint Treatment outcome for metastatic papillary renal cell carcinoma patients
    Ellen A Ronnen
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 107:2617-21. 2006
  9. ncbi request reprint Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy
    Ellen A Ronnen
    Department of Medicine, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:6999-7004. 2005
  10. pmc Clinical outcome and predictors of survival in late relapse of germ cell tumor
    David S Sharp
    Department of Urology, Memorial Sloan Kettering Cancer Center, 353 E 68th St, New York, NY 10021, USA
    J Clin Oncol 26:5524-9. 2008

Collaborators

Detail Information

Publications22

  1. ncbi request reprint Adjuvant chemotherapy for stage II nonseminomatous germ-cell tumors
    G Varuni Kondagunta
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Semin Urol Oncol 20:239-43. 2002
    ..A prospective trial of 2 cycles of etoposide plus cisplatin adjuvant chemotherapy for patients with pN2 tumors showed that this regimen was highly effective in achieving relapse-free survival...
  2. ncbi request reprint Chemotherapy for advanced germ cell tumors
    G Varuni Kondagunta
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:5493-502. 2006
    ..This review summarizes the prognostic criteria on which treatment decisions may be based, and outlines the current treatment approaches...
  3. ncbi request reprint Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors
    G Varuni Kondagunta
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:85-90. 2007
    ..This prospective trial followed a similarly designed report of TICE, which used a different means of carboplatin dosing...
  4. ncbi request reprint Adjuvant chemotherapy for stage II nonseminomatous germ cell tumors
    G Varuni Kondagunta
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Urol Clin North Am 34:179-85; abstract ix. 2007
    ..In contrast, patients who have high-volume nodal involvement at RPLND have a relapse rate of 50% to 90% with surveillance alone, and adjuvant chemotherapy is the preferable option in this group...
  5. ncbi request reprint Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors
    G Varuni Kondagunta
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 23:9290-4. 2005
    ....
  6. ncbi request reprint Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors
    G Varuni Kondagunta
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:6549-55. 2005
    ..The efficacy of paclitaxel was evaluated in combination with ifosfamide and cisplatin as second-line chemotherapy for patients with relapsed testicular germ cell tumors (GCTs)...
  7. ncbi request reprint Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy
    G Varuni Kondagunta
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 22:464-7. 2004
    ....
  8. ncbi request reprint Treatment outcome for metastatic papillary renal cell carcinoma patients
    Ellen A Ronnen
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 107:2617-21. 2006
    ..The current retrospective study sought to define clinical features and outcome data for metastatic papillary RCC...
  9. ncbi request reprint Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy
    Ellen A Ronnen
    Department of Medicine, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:6999-7004. 2005
    ..To define the incidence, clinical features, and outcome to salvage chemotherapy in patients with late-relapse germ cell tumor (GCT) after a complete response to first-line chemotherapy...
  10. pmc Clinical outcome and predictors of survival in late relapse of germ cell tumor
    David S Sharp
    Department of Urology, Memorial Sloan Kettering Cancer Center, 353 E 68th St, New York, NY 10021, USA
    J Clin Oncol 26:5524-9. 2008
    ..Late relapse (LR) of germ cell tumor (GCT) is a well recognized entity associated with poor survival. We report on our experience with LR and determine predictors of survival...
  11. ncbi request reprint Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma
    Premal H Patel
    Genitourinary Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 26:273-6. 2008
    ..Toxicities included fatigue, hyperglycemia, dyspnea, and myelosuppression with decreased hemoglobin, lymphopenia, and neutropenia. Lenalidomide is tolerable, but no objective responses were observed in this clinical trial...
  12. ncbi request reprint A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma
    Ellen A Ronnen
    From the Genitourinary Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Invest New Drugs 24:543-6. 2006
    ..Six of the 20 patients required dose reduction. At the dose and schedule used in this trial, 17-AAG did not achieve objective response in the treatment of clear cell or papillary renal cell carcinoma patients...
  13. ncbi request reprint Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma
    Darren R Feldman
    Genitourinary Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Genitourin Cancer 6:25-30. 2008
    ..In this study, the efficacy and toxicity of pegylated IFN was assessed in patients with metastatic renal cell carcinoma (mRCC)...
  14. ncbi request reprint Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors
    Darren R Feldman
    Genitourinary Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Invest New Drugs 25:487-90. 2007
    ..For patients who had previously received taxane therapy, ixabepilone was not efficacious in the treatment of cisplatin-refractory GCT...
  15. ncbi request reprint Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors
    Scott E Eggener
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 109:528-35. 2007
    ..The authors assessed their institutional experience of retroperitoneal lymph node dissection (RPLND) after multiple chemotherapy regimens for advanced GCT...
  16. ncbi request reprint Long-term response with sunitinib for metastatic renal cell carcinoma
    Ellen A Ronnen
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 68:672.e19-20. 2006
    ..This case report illustrates the long-term response to sunitinib for patients with metastatic renal cell carcinoma...
  17. ncbi request reprint Phase II trial of bortezomib for patients with advanced renal cell carcinoma
    G Varuni Kondagunta
    Genitourinary Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:3720-5. 2004
    ..To assess the efficacy and toxicity of bortezomib (Velcade; Milennium Pharmaceuticals Inc, Cambridge, MA; formerly PS-341) in patients with metastatic renal cell carcinoma (RCC)...
  18. ncbi request reprint Recommendations of follow-up after treatment of germ cell tumors
    G Varuni Kondagunta
    Department of Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Semin Oncol 30:382-9. 2003
    ..Optimal means of imaging and frequency of physician visits and serum marker level measurements need to be further addressed...
  19. ncbi request reprint Interferon-alpha resistance associated genes in renal cell carcinoma identified by expression profiling
    James E Korkola
    Department of Cell Biology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 177:1264-8; discussion 1268. 2007
    ..We identified differentially expressed genes associated with response to pegylated interferon-alpha treatment in patients with renal cell carcinoma...
  20. ncbi request reprint Management of difficult germ-cell tumors
    Christie J Moore
    Department of Medicine, Division of Hematology Oncology, Oregon Health and Science University, Portland, Oregon, USA
    Oncology (Williston Park) 20:1565-70, 1575; discussion 1575-6. 2006
    ..In a series of case presentations, we review the evaluation and management of patients with persistent elevation of serum tumor markers and postchemotherapy residual radiographic abnormalities...
  21. ncbi request reprint Medullary renal cell carcinoma and response to therapy with bortezomib
    Ellen A Ronnen
    J Clin Oncol 24:e14. 2006
  22. doi request reprint Expression of prostate-specific membrane antigen in renal cortical tumors
    Hikmat A Al-Ahmadie
    Department of Pathology, University of Chicago, Chicago, IL, USA
    Mod Pathol 21:727-32. 2008
    ....